65,437 trials
Aging · Accidental Fall
Primary: Medically Treated Falls — 328; 349 Participants — p=0.11
ALS
Primary: Dose Limiting Toxicities (DLT) — 1; 2 Participants
Healthy Volunteers
Primary: Treatment Phase: Drug Liking (Maximum Effect [Emax]) "At This Moment" as Assessed Using Bipolar Visual Analogue Scale (VAS) — 56.7; 57.3; 56.5; 88.5 score on a scale
Usher Syndrome, Type 1B
Primary: BCVA - Better Seeing Eyes — -2.26 ETDRS score — p=<0.01
Hematologic Malignancy
Primary: Proportion of Patients Undergoing an Allo HCT Transplant Who Have a KIR Favorable Donor. — 23; 21 Participants
Chronic Plaque Psoriasis · Moderate to Severe Chronic Plaque Psoriasis
Primary: Number of Treatment Emergent Adverse Events (TEAEs) Adjusted by Duration of Subject Exposure to Investigational Medicinal Product (IMP) — 97.83; 179.68; 79.02; 77.11 no…
Fluid Loss
Primary: Characterize Changes in the Relative Index During an Apheresis Procedure — 94.9; 99.3 Relative Index
Bipolar Disorder · Cognitive Ability, General
Primary: Change From Baseline: Test of Strategic Learning — 2.35; 3.04 score on a scale — p=0.040
Laryngoscopy
Primary: Rate of Successful Intubation With One Attempt — 132; 119 Participants — p=0.0002
COVID-19 · SARS CoV 2 Infection
Primary: Test Results Comparison Between LumiraDx and GenScript — 0.097 Unitless
Healthy
Primary: Placebo-Adjusted Change From Baseline in QT Interval Corrected Using Fridericia's Formula (QTcF) at Expected Maximum Concentration (Cmax) on Day 3 for Sisunatovir…
Gestational Diabetes
Primary: Numbers Diagnosed With Gestational Diabetes — 7; 6 Participants — p=0.639
Overweight
Primary: Number of Participants With Treatment-Emergent Adverse Events as a Measure of Safety and Tolerability — 3 Participants
Nocturnal Enuresis
Primary: Wet Nights — 2.4; 4.6 wet nights per week
Renal Transplant
Primary: Skin Autofluorescence (SAF) Levels at 6 Months — 2.8; 2.8 Arbitrary units